Sulfonylureas and the risk of myocardial infarction

Metabolism: Clinical and Experimental

Volumn 55, Issue SUPPL. 1, 2006, Pages

  Thisted, Henriette ^a   Johnsen, Søren Paaske ^a   Rungby, Jørgen ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BEZAFIBRATE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; METFORMIN; NITRATE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; THROMBOCYTE SLOWING FACTOR; TOLBUTAMIDE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; HEART INFARCTION; HEART INFARCTION PREVENTION; HUMAN; HYPOGLYCEMIA; HYPOTHESIS; ISCHEMIC PRECONDITIONING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 33646051555     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.02.004     Document Type: Article

References (43)

1. Beck-Nielsen H., Hother-Nielsen O., and Pedersen O. Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: an overview. Diabet Med 5 (1988) 613-620
2. Jennings P.E. Vascular benefits of gliclazide beyond glycaemic control. Metabolism 49 10 Suppl 2 (2000) 17-20
3. Cacciapuoti F., Spiezia R., Bianchi U., Lama D., D'Avino M., and Varricchio M. Effectiveness of glibenclamide on myocardial ischaemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus. Am J Cardiol 67 (1991) 843-847
4. Downey J.M. An explanation for the reported observation that ATP dependent potassium channel openers mimic preconditioning. Cardiovasc Res 27 (1993) 1565
5. Gribble F.M., Tucker S.J., Seino S., and Ashcroft F.M. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels. Diabetes 47 (1998) 1412-1418
6. Gribble F.M., and Reiman F. Sulfonylurea action revisited: the post-cloning era. Diabetologia 46 (2003) 875-891
7. Geisen K., Vegh A., Krause E., and Papp J.G. Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res 28 (1996) 496-507
8. Riveline J.P., Danchin N., Ledru F., Varroud-Vial M., and Charpentier G. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab 29 (2003) 207-222
9. Maddock H.L., Siedlecka S.M., and Yellon D.M. Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc Drugs Ther 18 (2004) 113-119
10. Klepzig H., Kober G., Matter C., Luus H., Schneider H., Boedeker K.H., et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 20 (1999) 439-446
11. Lee T.M., and Chou T.F. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 88 (2003) 531-537
12. Beckman J.A., Creager M.A., and Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287 (2002) 2570-2581
13. Rytter L., Troelsen S., and Beck-Nielsen H. Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care 8 (1985) 230-254
14. Cooper R.S., Pacold I.V., and Ford E.S. Age-related differences in case-fatality rates among diabetic patients with myocardial infarction. Findings from National Hospital Discharge Survey, 1979-1987. Diabetes Care 14 (1991) 903-908
15. Meinert C.L., Knatterud G.L., Prout T.E., and Klimt C.R. A study of the effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19 Suppl (1970) 830
16. Boyle D., Hadden D.R., Bhatia S.K., Montgomery D.A., and Weaver J.A. Ischaemic heart-disease in diabetics. A prospective study. Lancet 1 (1972) 338-339
17. Hadden D.R., Montgomery D.A., and Weaver J.A. Myocardial infarction in maturity-onset diabetics. A retrospective study. Lancet 1 (1972) 335-338
18. Soler N.G., Pentecost B.L., Bennett M.A., FitzGerald M.G., Lamb P., and Malins J.M. Coronary care for myocardial infarction in diabetics. Lancet 1 (1974) 475-477
19. Soler N.G., Bennett M.A., Pentecost B.L., FitzGerald M.G., and Malins J.M. Myocardial infarction in diabetics. Q J Med 44 (1975) 125-132
20. Gustafsson I., Hildebrandt P., Seibaek M., Melchior T., Torp-Pedersen C., Kober L., et al. Long-term prognosis of diabetic patients with myocardial infarction: relation to antidiabetic treatment regimen. The TRACE Study Group. Eur Heart J 21 (2000) 1937-1943
21. Gustafsson I., Hildebrandt P., Seibaek M., Melchior T., Torp-Pedersen C., Kober L., et al. Prognosis of diabetic patients with MI. Cardiol Rev 18 (2001) 24-27
22. Aronow W.S., and Ahn C. Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone. Am J Cardiol 88 (2001) 556-557
23. Garratt K.N., Brady P.A., Hassinger N.L., Grill D.E., Terzic A., and Holmes Jr. D.R. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 33 (1999) 119-124
24. O'Keefe J.H., Blackstone E.H., Sergeant P., and McCallister B.D. The optimal mode of coronary revascularization for diabetics. A risk-adjusted long-term study comparing coronary angioplasty and coronary bypass surgery. Eur Heart J 19 (1998) 1696-1703
25. Knowler W.C., Sartor G., Melander A., and Schersten B. Glucose tolerance and mortality, including a substudy of tolbutamide treatment. Diabetologia 40 (1997) 680-686
26. Sartor G., Schersten B., Carlstrom S., Melander A., Norden A., and Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 29 (1980) 41-49
27. Paasikivi J., and Wahlberg F. Preventive tolbutamide treatment and arterial disease in mild hyperglycaemia. Diabetologia 7 (1971) 323-327
28. Danchin N., Charpentier G., Ledru F., Vaur L., Gueret P., Hanania G., et al. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry. Diabetes Metab Res Rev 21 (2004) 143-149
29. Keen H., Jarrett R.J., Chlouverakis C., and Boyns D.R. The effect of treatment of moderate hyperglycaemia on the incidence of arterial disease. Postgrad Med J Suppl (1968) 960-965
30. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 837-853
31. Fidel J., and Nelken L. Fatal vascular complications in diabetic patients treated by diet, sulfonylureas and insulin. A retrospective study. Isr J Med Sci 10 (1974) 702-706
32. Fisman E.Z., Tenenbaum A., Benderly M., Goldbourt U., Behar S., and Motro M. Antihyperglycaemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. Cardiology 91 (1999) 195-202
33. Halkin A., Roth A., Jonas M., and Behar S. Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction. J Thromb Thrombolysis 12 (2001) 177-184
34. Brady P.A., Al Suwaidi J., Kopecky S.L., and Terzic A. Sulfonylureas and mortality in diabetic patients after myocardial infarction. Circulation 97 (1998) 709-710
35. Jollis J.G., Simpson Jr. R.J., Cascio W.E., Chowdhury M.K., Crouse Jr. J.R., and Smith Jr. S.C. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J 138 5 Pt 1 (1999) S376-S380
36. Klamann A., Sarfert P., Launhardt V., Schulte G., Schmiegel W.H., and Nauck M.A. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J 21 (2000) 220-229
37. Davis T.M., Parsons R.W., Broadhurst R.J., Hobbs M.S., and Jamrozik K. Arrhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment. Diabetes Care 21 (1998) 637-640
38. Ulvenstam G., Aberg A., Bergstrand R., Johansson S., Pennert K., Vedin A., et al. Long-term prognosis after myocardial infarction in men with diabetes. Diabetes 34 (1985) 787-792
39. Stevens R.J., Coleman R.L., Adler A.I., Stratton I.M., Matthews D.R., and Holman R.R. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 27 (2004) 201-207
40. Meier J.J., Deifuss S., Klamann A., Schmiegel W., and Nauck M.A. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA). Exp Clin Endocrinol Diabetes 111 (2003) 344-350
41. Fisman E.Z., Tenenbaum A., Boyko V., Benderly M., Adler Y., Friedensohn A., et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 24 (2001) 151-158
42. Johnsen SP, Monster TBM, Thisted H, Olsen ML, McLaughlin JK, Sørensen HT, et al. The risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther. [in press].
43. www.oxfordvision2020.org. Oxford Vision home page 2005.